Breath Test for Early Detection of Lung Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To demonstrate and validate a breath test for detection of early stage lung cancer that could potentially reduce number of deaths.
| Condition |
|---|
|
Lung Neoplasms |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Breath Test Assay for the Adjunctive Detection of Lung Cancer |
- Sensitivity and specificity of the breath test as compared to CT and pathology to support primary lung cancer diagnosis. [ Time Frame: 30 days after completion. ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 600 |
| Study Start Date: | June 2008 |
| Estimated Study Completion Date: | March 2012 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT
|
|
2
Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis.
|
|
3
Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection.
|
|
4
Apparently healthy individuals having no signs and symptoms of lung carcinoma.
|
Detailed Description:
This is a multicenter study comparing several groups of subjects with and without lung cancer by CT scan, biopsy and the breath test. The breath test will be performed to validate the methodology and the predictive algorithm that were previously developed.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Group 1. Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT
Group 2. Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis.
Group 3. Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection.
Group 4. Apparently healthy individuals having no signs and symptoms of lung carcinoma.
Group 1 - Asymptomatic High Risk Subjects
Inclusion criteria
- Patient is willing and able to cooperate with study and give signed informed consent to participate.
- Patient has had (or will have) chest imaging with spiral CT within 7 days of breath test.
- Age at least 18 years.
- History of at least 10 pack-years of cigarette smoking.
- Provide written informed consent prior to admission into the study.
Exclusion criteria
1. Previously documented history of cancer of any site.
Group 2 - Symptomatic High Risk Subjects Without a Tissue Diagnosis
Inclusion criteria
- Patient is willing and able to cooperate with study and give signed informed consent to participate.
- Patient does not have a tissue diagnosis of pulmonary disease.
- Patient is undergoing evaluation for an unexplained pulmonary illness which is clinically consistent with lung cancer. This includes patients with unexplained symptoms (e.g. chronic unexplained cough or hemoptysis), unexplained signs (e.g. weight loss, lymphadenopathy) or unexplained investigations (e.g. an abnormal chest x-ray).
- Actively smoking patients, as well as never smokers and former smokers are eligible for the study so long as a complete smoking consumption history can be recorded.
Exclusion criteria
1. Previously documented history of cancer of any other site.
Group 3 - Symptomatic High Risk Subjects with a Tissue Diagnosis
Inclusion criteria
- Patient is willing and able to cooperate with study and give signed informed consent to participate.
- Patient has a tissue diagnosis of a. lung cancer. or b. pulmonary disease other than lung cancer e.g. sarcoidosis, COPD, or pulmonary infection.
- A diagnosis of lung cancer is defined as cytologic or histologic confirmation of lung cancer by bronchoscopic/thoracoscopic means, sputum cytology, percutaneous fine needle aspiration biopsy. Patients may have either non-small cell lung cancer or small cell lung cancer.
- Breath VOC collection will be obtained prior to any invasive procedure e.g. thoracotomy, mediastinoscopy or mediastinotomy.
- Actively smoking patients, as well as never smokers and former smokers are eligible for the study so long as a complete smoking consumption history can be recorded.
Exclusion criteria
1. Previously documented history of cancer of any other site.
Group 4 - Apparently healthy subjects
Inclusion criteria
- Willingness to follow protocol requirements as evidenced by written, informed consent.
- Healthy, male or female subjects, ages 18 and older.
- Subjects who are non smokers having no signs or symptoms of lung carcinoma
Exclusion Criteria
1. Any active ongoing medical problems.
Contacts and Locations| United States, Delaware | |
| Christiana Hospital | Recruiting |
| Newark, Delaware, United States, 19718 | |
| Contact: Thomas Bauer 302-623-4530 TBauer@Christianacare.org | |
| Principal Investigator: Thomas Bauer, MD | |
| United States, Florida | |
| MD Anderson Cancer Center | Recruiting |
| Orlando, Florida, United States, 32806 | |
| Contact: Naren Ramakrishna, MD 407-648-3800 Alan.Forbes@orhs.org | |
| Principal Investigator: Alan R Forbes, MD, PhD | |
| United States, New York | |
| New York University Medical Center | Recruiting |
| New York, New York, United States, 10016 | |
| Contact: William N Rom, MD, MPH 212-263-6479 william.rom@med.nyu.edu | |
| Principal Investigator: Harvey I Pass, MD | |
| Sub-Investigator: William N Rom, MD, MPH | |
| United States, Washington | |
| Swedish Cancer Institute | Recruiting |
| Seattle, Washington, United States, 98104 | |
| Contact: Eric Vallieres, MD, FRCSC 206-215-6800 Eric.Vallieres@swedish.org | |
| Principal Investigator: Eric Vallieres, MD, FRCSC | |
| Principal Investigator: | Michael Phillips, MD, FACP | Menssana Research, Inc. |
More Information
No publications provided
| Responsible Party: | Michael Phillips/Sponsor, Menssana Research, Inc. |
| ClinicalTrials.gov Identifier: | NCT00639067 History of Changes |
| Other Study ID Numbers: | M08-01, NIH 5R44HL070411-05 |
| Study First Received: | March 12, 2008 |
| Last Updated: | June 23, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Menssana Research, Inc.:
|
Cancer of Lung Cancer of the Lung Lung Cancer Neoplasms, Lung |
Neoplasms, Pulmonary Pulmonary Cancer Pulmonary Neoplasms |
Additional relevant MeSH terms:
|
Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
Neoplasms by Site Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 19, 2013